Unlocking Novel Payloads for Antibody-Drug Conjugates Through Targeted Delivery of Hydroxyl-Linked Drugs via ALCO5
- Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Exploring novel conjugation technologies for stable conjugation and traceless release of hydroxy-containing cytotoxins with different intracellular MOAs
- Resulting ADCs are homogenous with a high DAR, have excellent linker stability, and exhibit excellent in vivo PK and efficacyÂ